IDO1 and neoplasm: MSNs encapsulating doxorubicin for co-delivering an IDO inhibitor could trigger the release of the IDO inhibitor into tumor extracellular vesicles and also the DOX to the intracellular lysosomal compartment, which were uptaken by IDO-expressing DCs reducing the proportion of immunosuppressive Tregs (Li et al., 2021).